ETNB News and Press, 89bio Inc. From 01/02/24

2024-01-02 11:12:57 ET Summary Madrigal Pharmaceuticals, Inc. stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. ...

SAN FRANCISCO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it...

2023-12-07 17:09:39 ET Gainers: Grayscale Solana Trust ( OTCQB:GSOL ) +7% . Accolade ( ACCD ) +5% . TPI Composites ( TPIC ) +5% . Travere Therapeutics ( TVTX ) +4% . 1-800-FLOWERS ( FLWS ) +3% . Losers: HashiCorp ( HCP ...

2023-12-07 07:54:08 ET More on 89bio 89bio: Despite Peer Trial Setback, Potential Remains In NASH 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio announces proposed underwritten public offering of commo...

SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pri...

2023-12-06 18:59:01 ET Summary 89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMM...

2023-12-06 16:39:37 ET More on 89bio 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio aligns with regulators on Phase 3 trials for NASH candidate 89bio gains FDA breakthrough status for NASH candidate ...

SAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it...

2023-12-06 01:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-04 10:54:59 ET More on 89bio 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio gains FDA breakthrough status for NASH candidate Seeking Alpha’s Quant Rating on 89bio Historical earnings ...